Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 avr. 2018 08h00 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress

3-month Phase 2 data indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained serum uric acid control, fewer flares, and less frequent dosing compared with...
03 avr. 2018 08h00 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress on April 10, 2018

WATERTOWN, Mass., April 03, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
20 mars 2018 16h01 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Needham Healthcare Conference on March 27, 2018

WATERTOWN, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
15 mars 2018 08h00 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

SEL-212 Severe Gout Program on Track; Additional Phase 2 Data for Higher Dose Cohorts to be Presented on April 9th or 10th, 2018 at PANLAR CongressPhase 1 Clinical Trial of SEL-403 for Mesothelioma...
12 mars 2018 08h00 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma

WATERTOWN, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
08 mars 2018 08h00 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Report Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15, 2018

WATERTOWN, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
09 janv. 2018 08h00 HE | Source: Selecta Biosciences, Inc.

Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of Recombinant Immunotoxin LMB-100 When Combined with SVP-Rapamycin

Selecta’s Immune Tolerance SVP Platform Also Discussed in Scientific American’s January 2018 Issue WATERTOWN, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a...
02 janv. 2018 08h05 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy

WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
02 janv. 2018 08h00 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences Announces CEO’s Intent to Retire and Transition Plan

Dr. Werner Cautreels Plans Retirement at the End of 2018Dr. Omid Farokhzad Appointed Chairman of the Board WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc....
13 nov. 2017 08h00 HE | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Webcast Investor Conference Presentations This Week

WATERTOWN, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...

Page précédente